GSK has confirmed that it has taken the first step to appeal the Delaware Superior Court's recent Daubert decision, which allows plaintiffs to testify as experts in the Zantac (ranitidine) litigation in Delaware.

' GSK strongly disagrees with the Delaware Superior Court's decision and has filed a petition with the court to appeal to the Delaware Supreme Court for review of the decision. Pfizer, Sanofi and Boehringer Ingelheim are all parties to the petition' says the group.

GSK also welcomes the plaintiff's voluntary dismissal of the forthcoming Zantac (Kasza) case, which was due to go to trial in an Illinois state court on June 10, 2024.

' Following 16 epidemiological studies of human data on the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of cancer ' says the group.

' GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and its shareholders', says management.

Copyright (c) 2024 All rights reserved.